Literature for NK3201 (S01.140 inhibitor)

(Topics flags: I Inhibitor. To select only the references relevant to a single topic, click the link above. See explanation.)

2009
1. Matsumoto,C., Hayashi,T., Kitada,K., Yamashita,C., Miyamura,M., Mori,T., Ukimura,A., Ohkita,M., Jin,D., Takai,S., Miyazaki,M., Okada,Y., Kitaura,Y. and Matsumura,Y.
   Chymase plays an important role in left ventricular remodeling induced by intermittent hypoxia in mice
   Hypertension54, 164-171. PubMed  Europe PubMed DOI  I
2006
2. Kanemitsu,H., Takai,S., Tsuneyoshi,H., Nishina,T., Yoshikawa,K., Miyazaki,M., Ikeda,T. and Komeda,M.
   Chymase inhibition prevents cardiac fibrosis and dysfunction after myocardial infarction in rats
   Hypertens Res29, 57-64. PubMed  Europe PubMed DOI  I
2004
3. [YEAR:1-3-2004]Doggrell,S.A. and Wanstall,J.C.
   Vascular chymase: pathophysiological role and therapeutic potential of inhibition
   Cardiovasc Res61, 653-662. PubMed  Europe PubMed DOI  I
2003
4. Takai,S., Sakonjo,H., Fukuda,K., Jin,D., Sakaguchi,M., Kamoshita,K., Ishida,K., Sukenaga,Y. and Miyazaki,M.
   A novel chymase inhibitor, 2-(5-formylamino-6-oxo-2-phenyl-1,6-dihydropyrimidine-1-yl)-N-[[,4-dioxo-1-phenyl-7-(2-pyridyloxy)]2-heptyl]acetamide (NK3201), suppressed intimal hyperplasia after balloon injury
   J Pharmacol Exp Ther304, 841-844. PubMed  Europe PubMed DOI  I